###begin article-title 0
###xml 93 98 <span type="species:ncbi:9606">human</span>
Two novel phosphatidylinositol-4-phosphate 5-kinase type Igamma splice variants expressed in human cells display distinctive cellular targeting
###end article-title 0
###begin p 1
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
2The authors declare they have no competing financial interests.
###end p 1
###begin p 2
The mRNA and peptide sequences of PIPKIgamma_v4 and PIPKIgamma_v5, including the sequenced region of each splice variant's 3'-UTR (untranslated region) sequence, will appear in the GenBank(R), EMBL, DDBJ and GSDB Nucleotide Sequence Databases under the accession numbers FJ965536 and FJ965537 respectively.
###end p 2
###begin p 3
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 243 244 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 402 403 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 441 442 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 442 443 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 771 779 763 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1757 1758 1721 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1758 1759 1722 1723 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 629 634 <span type="species:ncbi:9606">human</span>
###xml 1057 1062 <span type="species:ncbi:9606">Human</span>
The generation of various phosphoinositide messenger molecules at distinct locations within the cell is mediated via the specific targeting of different isoforms and splice variants of phosphoinositide kinases. The lipid messenger PtdIns(4,5)P2 is generated by several of these enzymes when targeted to distinct cellular compartments. Several splice variants of the type Igamma isoform of PIPK (PtdIns4P 5-kinase), which generate PtdIns(4,5)P2, have been identified, and each splice variant is thought to serve a unique functional role within cells. Here, we have identified two novel C-terminal splice variants of PIPKIgamma in human cells consisting of 700 and 707 amino acids. These two splice variants are expressed in multiple tissue types and display PIPK activity in vitro. Interestingly, both of these novel splice variants display distinct subcellular targeting. With the addition of these two new splice isoforms, there are minimally five PIPKIgamma splice variants that have been identified in mammals. Therefore, we propose the use of the HUGO (Human Genome Organization) nomenclature in the naming of the splice isoforms. PIPKIgamma_i4 (700 amino acids) is present in the nucleus, a targeting pattern that has not been previously observed in any PIPKIgamma splice variant. PIPKIgamma_i5 (707 amino acids) is targeted to intracellular vesicle-like structures, where it co-localizes with markers of several types of endosomal compartments. As occurs with other PIPKIgamma splice variants, the distinctive C-terminal sequences of PIPKIgamma_i4 and PIPKIgamma_i5 may facilitate association with unique protein targeting factors, thereby localizing the kinases to their appropriate cellular subdomains for the site-specific generation of PtdIns(4,5)P2.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>n</italic></sub>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 326 327 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 327 328 327 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 473 474 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 474 475 474 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 704 705 704 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 705 706 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 819 820 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 820 821 820 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1066 1067 1066 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1068 1069 1068 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1070 1071 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1124 1125 1124 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1125 1126 1125 1126 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1226 1227 1226 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1228 1229 1228 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1230 1231 1230 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1259 1260 1259 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1261 1262 1261 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1263 1264 1263 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1295 1296 1295 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1297 1299 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1300 1302 1300 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1334 1336 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1337 1339 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1362 1364 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
The signalling pathways that utilize members of the PtdInsPn family of lipids to transduce messages from one functional complex to another are as distinct as they are complex. PtdIns(4,5)P2 is positioned at the crossroads of many of these signalling cascades, as it may be metabolized by phospholipase C to generate Ins(1,4,5)P3 and 1,2-diacylglycerol, further phosphorylated at the 3-position of the inositol ring by phosphatidylinositol 3-kinase to generate PtdIns(3,4,5)P3 [1] or used directly as a messenger molecule by binding to proteins containing PH (pleckstrin homology), PX (phox homology), FERM (band 4.1, ezrin, radixin, moesin) or comparable domains [1,2]. However, the method of PtdIns(4,5)P2 generation utilized in these pathways results in its availability being far from ubiquitous. Rather, PtdIns(4,5)P2 seems to be synthesized in a highly site-specific manner at distinct subcellular locales where it is directly utilized as a signalling molecule, thereby modulating the activity, conformation, assembly or disassembly of proteins at these sites [1,3,4]. The spatial and temporal metabolism of PtdIns(4,5)P2 has emerged as a crucial regulator of multiple cellular processes, including actin reorganization [1,5,6], focal-adhesion dynamics [1,7-9], endocytosis and exocytosis [4,10-19], nuclear signalling pathways [20,21] and gene expression [22].
###end p 5
###begin p 6
###xml 25 26 25 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 118 119 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 291 293 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 504 505 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 505 506 490 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 676 677 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 678 680 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 816 817 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 818 819 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 820 822 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
Most cellular PtdIns(4,5)P2 generation is fulfilled by the alpha, beta and gamma isoforms of the type I PIPKs (PtdIns4P 5-kinases). Although retaining high homology within the lipid kinase domain, each isoform exhibits a distinct subcellular localization pattern and functional specificity [23]. It is believed that the N- and C-terminal sequence divergence of each PIPKI isoform contributes to this diversity in targeting and function. PIPKIalpha participates in both nuclear and cytoplasmic PtdIns(4,5)P2 generation, where it has been implicated in the regulation of RNA polyadenlyation machinery and growth-factor-induced reorganization of the cytoskeletal superstructure [3,24]. The cellular roles of PIPKIbeta are less defined, but a function for PIPKIbeta in actin assembly and endocytosis has been suggested [1,3,23].
###end p 6
###begin p 7
###xml 115 116 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 116 117 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 264 265 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 266 267 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 268 269 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 298 300 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 301 303 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 493 495 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 634 636 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 972 973 940 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 974 975 942 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 976 978 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 979 981 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 982 984 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 985 987 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 988 990 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1188 1190 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 1221 1223 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1318 1320 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1402 1404 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1405 1407 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1561 1562 1517 1518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1562 1563 1518 1519 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1622 1623 1578 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1623 1624 1579 1580 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1637 1639 1593 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 382 387 <span type="species:ncbi:9606">human</span>
The newest member of the type I family, PIPKIgamma (type Igamma PIPK), is a workhorse for site-specific PtdIns(4,5)P2 generation in a plethora of cytoplasmic processes. PIPKIgamma is a fundamental regulator of the assembly and disassembly of sites of cell-matrix [1,8,9] and cell-cell interaction [17,25] termed focal adhesions and adherens junctions respectively. Importantly, the human PIPKIgamma is known to encode at least two alternative splice variants, PIPKIgamma640 and PIPKIgamma668 [26]. These splice variants differ by the inclusion of exon 17, which encodes a 28-amino-acid C-terminal extension specific to PIPKIgamma668 [26]. This 28-amino-acid extension has been demonstrated to confer specific subcellular targeting and function on PIPKIgamma668, where it consequently regulates focal adhesion dynamics, EGF (epidermal growth factor)-stimulated directional migration, basolateral targeting of E-cadherin, and endocytosis of the TfnR (transferrin receptor) [8,9,13,14,16-18,27]. Aside from mediating specific protein-protein interactions, this extension also affords several methods of regulating PIPKIgamma668 activity, as it is tyrosine- and serine-phosphorylated by Src [28] and cyclin-dependent kinase [29] respectively. In addition, PIPKIgamma can be directly phosphorylated by EGFR (EGF receptor) [27]. These phosphorylation events are in turn antagonized by specific phosphatases [29,30]. In the absence of a specific C-terminal extension, PIPKIgamma640 also plays a specific cellular role, as it is the major contributor of the PtdIns(4,5)P2 utilized in G-protein-coupled-receptor-mediated Ins(1,4,5)P3 generation [31].
###end p 7
###begin p 8
###xml 130 132 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 134 136 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 395 397 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 566 568 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1375 1382 1347 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
###xml 91 94 <span type="species:ncbi:10116">rat</span>
###xml 499 504 <span type="species:ncbi:9606">human</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
###xml 670 675 <span type="species:ncbi:9606">human</span>
###xml 1347 1352 <span type="species:ncbi:9606">Human</span>
A third PIPKIgamma splice variant consisting of 688 amino acids was described in mouse and rat neuronal tissue by Giudici et al. [32, 33]. In addition to containing the 28-amino-acid C-terminal extension of PIPKIgamma668, this novel splice variant also contained a unique 26-amino-acid sequence inserted prior to the extension first defined in PIPKIgamma668 and appears to be neuronal-specific [32]. Although Giudici et al. uncovered the presence of a sequence homologous with this insertion in the human genome, they did not confirm its existence in human tissues [32]. Here, we provide evidence that two unique PIPKIgamma C-terminal splice variants do indeed exist in human cells. The two novel splice variants consist of 700 and 707 amino acids, possess PIPK activity, and are expressed in a multitude of cell types and tissues. Importantly, these splice variants display subcellular localization patterns that are unique from PIPKIgamma640 or PIPKIgamma668, suggesting that each splice variant likely fills a distinct functional role within cells. Since the discovery of these two new splice variants further complicates the PIPKIgamma nomenclature, all further instances of PIP5K1C gene products mentioned in the present paper have been assigned nomenclature based on the guidelines established by the Genetic Nomenclature Committee of HUGO (Human Genome Organization) (Table 1). Following this convention, the unique PIPKIgamma mRNAs described herein are referred to as PIPKIgamma_v4 and PIPKIgamma_v5, whereas their protein products are termed PIPKIgamma_i4 and PIPKIgamma_i5.
###end p 8
###begin title 9
Summary of proposed revisions to PIP5K1C splice variant nomenclature
###end title 9
###begin p 10
* Splice variant not defined.
###end p 10
###begin p 11
dagger Partial exon.
###end p 11
###begin p 12
###xml 19 24 <span type="species:ncbi:9606">Human</span>
double daggerHGVS, Human Genome Variation Society.
###end p 12
###begin title 13
EXPERIMENTAL
###end title 13
###begin title 14
Cloning of PIPKIgamma splice variants
###end title 14
###begin p 15
mRNA from mammary epithelial cell line MCF10A was isolated using the Micro-FastTracktrade mark 2.0 mRNA Isolation Kit (Invitrogen). 3'-RACE (3' rapid amplification of cDNA ends) was performed with the GeneRacer system (Invitrogen) using primers specific to a portion of PIPKIgamma exon 16 (5'-GCCTCTGCTGCTGTTGAAGTAGAAA-3') and the supplied 3' adaptor primer according to the manufacturer's instructions. PCR products were run on agarose gels, and individual DNA bands were excised, purified and ligated into the pGEM-T Easy Vector (Promega). Full-length PIPKIgamma_v4 and PIPKIgamma_v5 were amplified from MCF10A cDNA using the 5' primer (5'-ATGGAGCTGGAGGTACCGGA-3') and 3' primer (5'-TTACCCAAAGCCCTTCTGGAAA-3').
###end p 15
###begin title 16
Expression constructs
###end title 16
###begin p 17
###xml 244 260 236 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 244 260 <span type="species:ncbi:562">Escherichia coli</span>
Human PIPKIgamma splice variants were amplified via PCR for insertion into the pCMV-HA vector (Clontech). Upon insertion into expression vectors, the 3'-UTR (untranslated region) of each PIPKIgamma splice variant was removed. For expression in Escherichia coli, PIPKI coding sequences were subcloned into pET28 (Novagen). PIPKIgamma point mutations were generated using PCR primer overlap extension with primers containing the desired mutations.
###end p 17
###begin title 18
Antibodies
###end title 18
###begin p 19
###xml 99 100 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 181 187 <span type="species:ncbi:9986">Rabbit</span>
###xml 901 912 <span type="species:ncbi:3704">horseradish</span>
Polyclonal antibodies towards the PIPKIgamma splice variants were created as previously described [8]. Anti-HA (haemagglutinin) monoclonal antibody HA.11 was obtained from Covance. Rabbit polyclonal anti-HA and anti-(lamin beta1) were purchased from Santa Cruz Biotechnology. Anti-beta-tubulin, anti-N-cadherin, anti-E-cadherin, anti-alpha-adaptin, anti-TfnR, anti-EEA1 (early endosome antigen 1) and anti-SC-35 (splicing factor, arginine/serine-rich 2) antibodies were purchased from BD Biosciences, and anti-actin antibody was obtained from MP Biomedicals. Anti-nucleolin and anti-CD63 antibodies were obtained from Millipore. Anti-LAMP1 (lysosomal-associated membrane protein 1) monoclonal antibody was from Abcam, and anti-talin was from Sigma-Aldrich. Alexa 350-, Alexa 488-, Alexa 555-, Alexa 647- and Pacific Blue-conjugated secondary antibodies were purchased from Molecular Probes. Secondary horseradish-peroxidase-conjugated antibodies for Western blotting were obtained from Jackson Immunoresearch Laboratories.
###end p 19
###begin title 20
Purification of recombinant protein
###end title 20
###begin p 21
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 234 235 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 235 238 226 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600</sub>
###xml 297 298 283 284 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sc>
###xml 357 358 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 422 429 402 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 75 82 <span type="species:ncbi:562">E. coli</span>
###xml 422 429 <span type="species:ncbi:562">E. coli</span>
PIPKI coding regions subcloned into the pET28 vector were transformed into E. coli Rosettatrade mark 2(DE3) competent cells from Novagen. Overnight starter cultures were expanded in 0.5 litre cultures in Luria Broth to an attenuance (D600) of </=0.6 and were then induced with 1 mM isopropyl beta-D-thiogalactoside for 3 h at 37 degreesC with agitation. His6 (hexahistidine)-tagged fusion proteins were then purified from E. coli lysates with His-Bindtrade mark resin (Novagen) according to the manufacturer's instructions.
###end p 21
###begin title 22
PIPKI lipid kinase activity assay
###end title 22
###begin p 23
###xml 69 70 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 128 130 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 131 133 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
The lipid kinase activity of PIPKI was assayed against 25 muM PtdIns4P micelles or Folch Brain Extract as previously described [17,34].
###end p 23
###begin title 24
Subcellular fractionation
###end title 24
###begin p 25
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 191 192 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 191 192 191 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 550 551 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 785 786 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 785 786 778 779 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 999 1000 979 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1094 1095 1074 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1094 1095 1074 1075 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
HeLa cells were plated at 1.3x106/10-cm-diameter plate and grown overnight. Cells were lifted with a non-enzymatic cell dissociation buffer (Sigma-Aldrich), collected by centrifugation (1000 g for 5 min at 4 degreesC), and washed twice in cold PBS. One half of the cell pellet was lysed directly in 2xloading buffer [1xloading buffer is 10 mM Tris, 5% (v/v) glycerol, 1% (w/v) SDS and 1% (v/v) 2-mercaptoethanol, pH 6.8] as a whole-cell lysate control. The remainder of the cells were resuspended in 300 mul Buffer A [10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl and 0.5 mM DTT (dithiothreitol)], vortex-mixed briefly and incubated on ice for 30 min. After the addition of 0.2% (v/v) Nonidet P40, cell lysis was verified by Trypan Blue exclusion and cells were then centrifuged at 300 g for 15 min at 4 degreesC. The cytoplasmic fraction was removed and the pellet containing nuclei was lysed for 30 min at 4 degreesC in 100 mul of buffer C [20 mM Hepes, 25% (v/v) glycerol, 450 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA and 0.5 mM DTT]. The nuclear lysate was then cleared by centrifugation at 16000 g for 15 min at 4 degreesC. The cytoplasmic, nuclear and whole-cell lysates were then quantified with Bradford's reagent (25 ml of phosphoric acid, 12.5 ml of ethanol and 25 mg of Coomassie Brilliant Blue; Bio-Rad Laboratories) before Western blotting.
###end p 25
###begin title 26
Cell culture and transfection
###end title 26
###begin p 27
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 75 81 <span type="species:ncbi:9913">bovine</span>
HeLa cells plated at 5.5x105 cells/60-mm-diameter plate in 10% (v/v) fetal bovine serum+Dulbecco's modified Eagle's medium were incubated overnight before transfection with 8 mug of total DNA and 9 mul of Lipofectaminetrade mark 2000 (Invitrogen). Cells were harvested for analysis at about 18 h post-transfection. For siRNA (small interfering RNA) knockdown of PIPKIgamma, HeLa cells were transfected with Lipofectaminetrade mark 2000 and either a non-targeting or pan-PIPKIgamma siRNA duplex (GCCACCUUCUUUCGAAGAA) and harvested at either 48 or 72 h post-transfection.
###end p 27
###begin title 28
Immunofluorescence and confocal microscopy
###end title 28
###begin p 29
MCF10A and HeLa cells were grown on glass coverslips placed inside six-well plates 24 h prior to transfection. Coverslips containing cells were washed in PBS at 37 degreesC, and then fixed with chilled methanol or 4% (w/v) paraformaldehyde, followed by permeabilization with 0.5% (v/v) Triton X-100 in PBS. The cells were then blocked for 1 h at room temperature (25 degreesC) in 3% (w/v) BSA (Jackson Immunoresearch Laboratories) in PBS. Primary-antibody incubation was performed at 37 degreesC for 2 h or 4 degreesC for 16 h, whereas incubation with fluorophore-conjugated secondary antibodies was performed at 37 degreesC for 30 min. Cells were washed in between incubation steps with 0.1% (v/v) Triton X-100 in PBS. Indirect immunofluorescence microscopy was performed on a Nikon Eclipse TE2000U instrument equipped with a Photometrics CoolSNAP CCD (charged coupled device) camera. Images were captured and further processed using MetaMorph (Molecular Devices) or AutoQuant (Media Cybernetics) cellular imaging software. Images were exported to Photoshop CS2 (Adobe) for final processing and assembly.
###end p 29
###begin title 30
Tissue and cell-line immunoblotting
###end title 30
###begin p 31
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 287 288 287 288 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 290 291 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 465 466 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 465 466 459 460 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>g</italic></bold>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 689 694 <span type="species:ncbi:10090">mouse</span>
Mouse tissue was excised from a CO2-asphyxiated C57BL/6 female mouse and flash-frozen in liquid nitrogen. Proteins were extracted from tissues by grinding with a tissue homogenizer into a buffer consisting of 20 mM Tris/HCl, pH 7.6, 1% (v/v) Triton X-100, 137 mM NaCl, 2 mM EDTA, 1 mM Na3VO4, 1 mM DTT and protease inhibitors. Tissue homogenates were rotated for 2 h at 4 degreesC to complete lysis. Lysates were cleared of tissue debris by centrifugation at 15000 g for 20 min at 4 degreesC. Protein concentrations were calculated using the BCA (bicinchoninic acid) protein quantification assay (Bio-Rad Laboratories) according to the manufacturer's instructions. For Western blotting of mouse tissue lysates, 20 mug of each tissue lysate was subjected to SDS/7.5%-(w/v)-PAGE. Cell line lysates were generated by scraping a 100-mm-diameter plate of each cell type into 1 ml of RIPA buffer [50 mM Tris/HCl, 150 mM NaCl, 1.0% (v/v) Nonidet P40, 0.5% (w/v) sodium deoxycholate, 1.0 mM EDTA and 0.1% (w/v) SDS, pH 7.4), supplemented with protease inhibitors, followed by incubation for 1 h at 4 degreesC. Lysates were cleared, quantified and 15 mug of each cell line lysate was analysed by Western blot as described above. A PageRuler Prestained Protein Ladder (Fermentas) or a Benchmark Prestained Protein Ladder (Invitrogen) was used as the molecular-mass standard for Western blotting.
###end p 31
###begin title 32
RESULTS
###end title 32
###begin title 33
###xml 45 50 <span type="species:ncbi:9606">human</span>
Identification of PIPKIgamma mRNAs in MCF10A human epithelial cells
###end title 33
###begin p 34
###xml 235 243 211 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1201 1209 1145 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human PIPKIgamma mRNA that encodes PIPKIgamma_i1 or PIPKIgamma_i2 contains 17 or 18 exons respectively, with exon 18 consisting of the translational stop codon for both proteins as well as a long 3'-UTR region (approximately3 kb) (Figure 1B). When Western-blotting cell lysates from MCF10A cells were incubated with a pan-PIPKIgamma antibody, an immunoreactive band was observed at a slightly greater molecular size than that attributable to PIPKIgamma_i2. This provided evidence that there may be other PIPKIgamma splice variants that have yet to be identified. In order to identify the putative novel PIPKIgamma species in MCF10A epithelial cells, mRNA was extracted from cells and subjected to reverse transcription-PCR. Initially, any unidentified splice variant was expected to share exon 18 as a 3'-UTR. In subsequent PCRs, primers were used that targeted internal exons, along with a primer targeting the 3'-UTR, to amplify PIPKIgamma mRNAs. These amplicons were subcloned into a T/A cloning vector and approximately50 clones per region were screened via restriction-enzyme digest and DNA sequencing for variations in exon structure. Although some variation of exon structure was observed (Figure 1B and results not shown), each alternative splicing event that was detected by this method resulted in a transcript that was shorter than PIPKIgamma_v2. Because the immunoreactive band we had observed in MCF10A lysates was of greater molecular size, these smaller splice variants were not characterized further.
###end p 34
###begin title 35
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human PIPKIgamma gene encodes at least four C-terminal splice variants
###end title 35
###begin p 36
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 399 400 383 384 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1187 1188 1139 1140 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1339 1342 1283 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">647</sup>
###xml 1348 1351 1292 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">653</sup>
###xml 1401 1404 1341 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">647</sup>
###xml 1410 1413 1350 1353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">653</sup>
###xml 428 433 <span type="species:ncbi:9606">human</span>
(A) The full-length PIPKIgamma_v4 and PIPKIgamma_v5 transcripts were amplified from MCF10A-epithelial-cell cDNA using a primer targeted to the conserved 5'-end of the PIPKIgamma transcript and a second primer matching the putative 3' alternatively spliced exon identified via 3'-RACE. The less prominent band running immediately below PIPKIgamma_v5 was also sequenced and found to be non-specific. (B) A revised exon map of the human PIPKIgamma gene illustrates the four major C-terminal splice variants that have been identified. The overall lengths of PIPKIgamma transcripts listed are approximate estimates based on the defined open reading frames plus the 3' untranslated region. Two novel exons, which have been termed exon 16b and 16c, make up the alternatively spliced C-termini of the PIPKIgamma_v4 and PIPKIgamma_v5 transcripts. Interestingly, the PIPKIgamma_v4 transcript is longer than that of PIPKIgamma_v5, but PIPKIgamma_v4 mRNA encodes a shorter protein, owing to a stop codon in exon 16b. PIPKIgamma transcripts were identified in our initial experiments that lacked portions of exons 3 or 5, or all of exon 14, but these splice variants were not further characterized. (C) CLUSTALW alignment of the C-terminal amino acid residues of the four PIPKIgamma splice variants. Note that part of the C-terminus of PIPKIgamma_i5 (W647IYSPRH653) is similar to the C-terminus of PIPKIgamma_i2 (W647VYSPLH653). The presence of a full stop (period) indicates the lack of a corresponding amino acid residue at the indicated position.
###end p 36
###begin p 37
###xml 1857 1865 1777 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 2030 2038 1942 1950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 637 642 <span type="species:ncbi:9606">human</span>
Since the previously described splice variants of PIPKIgamma display alternative splicing of the 3' end of their mRNA to encode a unique C-terminal tail region, we hypothesized that the unknown splice variant may contain a longer unique C-terminus distinct from that of PIPKIgamma_i2. The PIPKIgamma gene is quite long, being over 70 kb in length (chromosome 19; 3 581 182-3 651 445); however, the mRNA which encodes PIPKIgamma_v2 is only approximately5 kb. Although this is not uncommon, it leaves the possibility that other splicing events can incorporate sequences that are assumed to be intronic. Interestingly, introns 16-17 of the human PIPKIgamma sequence, which in PIPKIgamma pre-mRNA lies between the majority of the PIPKIgamma coding sequence and the 84 bp which encode the unique C-terminus of PIPKIgamma_i2, is also quite large (approximately5.3 kb). If another PIPKIgamma C-terminal splice variant were encoded by the PIPKIgamma gene, it is likely that this intron would contain the source sequence for the unique extension. With this in mind, we performed 3'-RACE on MCF10A cDNA using a forward primer directed towards exon 16. The amplicons were then analysed by agarose-gel electrophoresis, individual bands were extracted for ligation into a T/A vector, and the ligated inserts were sequenced. The sequence information obtained from 3'-RACE indicated the presence of a previously unidentified exon mapping to intron 16-17 (3 589 519-3 589 881) of the PIPKIgamma gene. PCR was then performed to amplify the full-length splice variant using a primer directed towards the known start codon of PIPKIgamma and the predicted stop codon and its 5' flanking sequence. This resulted in the identification of two splice variants containing the novel exon, which we have named according to HUGO guidelines as PIPKIgamma_v4 and PIPKIgamma_v5 (Table 1; Figure 1A). PIPKIgamma_v4 was predicted to contain a reading frame of 2103 nucleotides, whereas the reading frame of PIPKIgamma_v5 was expected to contain 2124 nucleotides (Figure 1B). Interestingly, both splice variants utilize the novel exon 16c. In the case of PIPKIgamma_v5, this exon encodes a unique 67-amino-acid C-terminus. By contrast, the unique C-terminus of PIPKIgamma_v4 is encoded by a second novel exon, 16b, whereas exon 16c makes up a portion of its 3'-UTR. Upon identification of the splice variant mRNAs in MCF10A cells, we then sought to determine whether these messages were evolutionarily conserved.
###end p 37
###begin title 38
The coding regions of PIPKIgamma_v4 and PIPKIgamma_v5 are evolutionarily conserved
###end title 38
###begin p 39
###xml 233 234 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 235 237 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 238 240 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 706 714 686 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 777 791 753 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Macaca mulatta</italic>
###xml 820 835 796 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pan troglodytes</italic>
###xml 1152 1160 1120 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1235 1237 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1798 1800 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 394 399 <span type="species:ncbi:9606">human</span>
###xml 777 791 <span type="species:ncbi:9544">Macaca mulatta</span>
###xml 793 807 <span type="species:ncbi:9544">rhesus macaque</span>
###xml 820 835 <span type="species:ncbi:9598">Pan troglodytes</span>
###xml 837 847 <span type="species:ncbi:9598">chimpanzee</span>
###xml 1098 1103 <span type="species:ncbi:10090">mouse</span>
###xml 1108 1111 <span type="species:ncbi:10116">rat</span>
###xml 1193 1198 <span type="species:ncbi:10090">mouse</span>
###xml 1256 1261 <span type="species:ncbi:10090">mouse</span>
###xml 1378 1383 <span type="species:ncbi:10090">mouse</span>
###xml 1427 1432 <span type="species:ncbi:9606">human</span>
###xml 1553 1558 <span type="species:ncbi:10090">mouse</span>
###xml 1672 1677 <span type="species:ncbi:10090">mouse</span>
###xml 1733 1738 <span type="species:ncbi:10090">mouse</span>
The PIPKIgamma_v2 splice variant has been conserved through evolution, as the DNA sequence encoding its distinctive 28-amino-acid C-terminal extension is present in most vertebrates, with a high level of conservation within mammals [1,26,32]. This conservation underlines the importance of this splice variant in multiple cellular functions. Using the unique C-terminal amino acid sequences of human PIPKIgamma_i4 and PIPKIgamma_i5, a thorough BLASTN search was performed of both the complete and incomplete genome assemblies available on ENSEMBL. Putative orthologues of PIPKIgamma_i5 were identified in multiple vertebrate species, indicating that the function of PIPKIgamma_i5 is most likely conserved (Figure 2). Interestingly, PIPKIgamma_i4 orthologues were identified in Macaca mulatta (rhesus macaque monkey) and Pan troglodytes (chimpanzee), but our search of translated sequence databases did not yield PIPKIgamma_i4 orthologues in the other species where sequence information was available. In contrast with this finding, the presence of the PIPKIgamma_i4 protein was observed in canine, mouse and rat cell lines via Western blot (see below; Figure 3D). Since a full assembly of the mouse genome has recently been completed [35], we searched the mouse PIPKIgamma gene for the PIPKIgamma_v4 coding sequence. We did observe a nucleotide sequence in introns 16-17 of the mouse PIPKIgamma gene that partially matches the human PIPKIgamma_v4 coding sequence. However, we have not been able to translate this sequence into a putative version of the mouse PIPKIgamma_i4 protein, owing to apparent gaps in the genomic sequence. Our unsuccessful attempts to identify the mouse PIPKIgamma_i4 orthologue reinforce the notion that the mouse genome assembly may require localized review and revision [35].
###end p 39
###begin title 40
PIPKIgamma_i4 and PIPKIgamma_i5 are evolutionarily conserved
###end title 40
###begin p 41
###xml 344 357 328 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C. familiaris</italic>
###xml 359 375 343 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Canis familiaris</italic>
###xml 383 392 367 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G. gallus</italic>
###xml 394 407 378 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gallus gallus</italic>
###xml 419 429 403 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H. sapiens</italic>
###xml 431 443 415 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Homo sapiens</italic>
###xml 451 462 435 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M. musculus</italic>
###xml 464 476 448 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mus musculus</italic>
###xml 491 504 475 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R. norvegicus</italic>
###xml 506 523 490 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rattus norvegicus</italic>
###xml 344 357 <span type="species:ncbi:9615">C. familiaris</span>
###xml 359 375 <span type="species:ncbi:9615">Canis familiaris</span>
###xml 377 380 <span type="species:ncbi:9615">dog</span>
###xml 383 392 <span type="species:ncbi:9031">G. gallus</span>
###xml 394 407 <span type="species:ncbi:9031">Gallus gallus</span>
###xml 409 416 <span type="species:ncbi:9031">chicken</span>
###xml 419 429 <span type="species:ncbi:9606">H. sapiens</span>
###xml 431 443 <span type="species:ncbi:9606">Homo sapiens</span>
###xml 445 448 <span type="species:ncbi:9606">man</span>
###xml 451 462 <span type="species:ncbi:10090">M. musculus</span>
###xml 464 476 <span type="species:ncbi:10090">Mus musculus</span>
###xml 478 489 <span type="species:ncbi:10090">house mouse</span>
###xml 491 504 <span type="species:ncbi:10116">R. norvegicus</span>
###xml 506 523 <span type="species:ncbi:10116">Rattus norvegicus</span>
###xml 525 535 <span type="species:ncbi:10116">Norway rat</span>
A CLUSTALW alignment of putative orthologues of PIPKIgamma_i4 and PIPKIgamma_i5 was created using sequence information in the ENSEMBL database. The C-terminal amino acid sequences of PIPKIgamma_i4 and PIPKIgamma_i5 were used to search the ENSEMBL sequence database for potential matches in other species. Key to species not already identified: C. familiaris, Canis familiaris (dog); G. gallus, Gallus gallus (chicken); H. sapiens, Homo sapiens (man); M. musculus, Mus musculus, house mouse; R. norvegicus, Rattus norvegicus, Norway rat.
###end p 41
###begin title 42
PIPKIgamma_v4 and PIPKIgamma_v5 transcripts are expressed as proteins
###end title 42
###begin p 43
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 329 330 317 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 701 702 677 678 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 915 916 883 884 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 960 965 <span type="species:ncbi:10090">mouse</span>
(A) The specificity of purified polyclonal antibodies toward the unique C-terminal splice variants of PIPKIgamma was tested via Western blot. HA-tagged PIPKIgamma constructs were transfected into HeLa cells, and Western blots of whole-cell lysates were probed with splice variant-specific anti-PIPKIgamma polyclonal antibodies. (B) To verify that the anti-PIPKIgamma polyclonal antibodies can recognize endogenous protein and are specific towards their intended splice variant, total PIPKIgamma was knocked down in HeLa cells using siRNA for 48 or 72 h. Cell lysates were Western-blotted using each of the anti-PIPKIgamma polyclonal antibodies, and anti-actin antibody was used as a loading control. (C) Expression of PIPKIgamma splice variants in several mammalian cell lines was determined by Western-blotting cell line lysates with anti-PIPKIgamma antibodies. Anti-actin antibody was used as a loading control. (D) Fresh tissue was extracted from a C57BL/6 mouse, lysed, and total soluble protein was quantified. A 20 mug portion of lysate was subjected to Western blotting with the anti-PIPKIgamma polyclonal antibodies to determine the tissue distribution of splice variants. Abbreviations: Ctrl., control; HA-Igamma, HA-tagged PIPKIgamma; IB:, immunoblot; Igamma_i5 (etc.), PIPKIgamma_i5; Lrg. Int., lareg intestine; pan-Igamma, pan-PIPKIgamma; Transfect., transfection. i_5 etc. designates the protein, whereas v_5 designates the mRNA.
###end p 43
###begin title 44
###xml 49 54 <span type="species:ncbi:9606">human</span>
PIPKIgamma_v4 and PIPKIgamma_v5 are expressed as human cellular proteins
###end title 44
###begin p 45
###xml 254 262 254 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 509 517 505 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 787 795 775 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 287 294 <span type="species:ncbi:9986">rabbits</span>
To verify that these unique messages were expressed in human cells as proteins, polyclonal antibodies were made to specifically detect each of the novel splice variants. Recombinant peptides corresponding to each C-terminus of the novel splice variants (Figure 1C) were used to immunize rabbits, and antibodies were affinity-purified from bulk sera over an antigen column. These antibodies were analysed by Western blotting HeLa cell lysates transfected with each of the PIPKIgamma splice variant constructs (Figure 3A). The antibodies specifically detected their target splice variant, with no evident cross-reactivity with other PIPKIgamma splice variants. The specificity of these antibodies was further confirmed by siRNA knockdown of total cellular PIPKIgamma and Western blotting (Figure 3B). The results of these Western blots confirm that the band detected by each splice variant antibody is the intended target protein.
###end p 45
###begin p 46
###xml 223 231 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 826 828 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 829 831 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:10090">mouse</span>
###xml 189 192 <span type="species:ncbi:10116">rat</span>
###xml 441 446 <span type="species:ncbi:9606">human</span>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
###xml 466 469 <span type="species:ncbi:10116">rat</span>
With functional and specific polyclonal antibodies towards PIPKIgamma_i4 and PIPKIgamma_i5, we were then able to Western-blot epithelial and fibroblast cell line lysates from human, mouse, rat and canine cells. As shown in Figure 3(C), each cell line tested via Western blot expressed both the PIPKIgamma_i4 and PIPKIgamma_i5 splice variants, with an apparent molecular mass of approx. 100 kDa. Since these splice variants are detectable in human, canine, mouse and rat cell lines, this confirms that the expression of PIPKIgamma_i4 and PIPKIgamma_i5 is evolutionarily conserved within mammals. Interestingly, PIPKIgamma_i4 appears as a tight doublet in some cell lines. PIPKIgamma_i2 also appears as several discrete bands via Western blotting, and this may be due to the phosphorylation events that occur on its C-terminus [27-29]. Therefore, PIPKIgamma_i4 may undergo phosphorylation or other post-translational modifications that affects its apparent molecular mass.
###end p 46
###begin p 47
###xml 229 237 224 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 429 431 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 432 434 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 435 437 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1318 1326 1281 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1460 1462 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1463 1465 1418 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1560 1562 1511 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1563 1565 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
###xml 323 328 <span type="species:ncbi:10090">mouse</span>
###xml 897 902 <span type="species:ncbi:10090">mouse</span>
###xml 957 962 <span type="species:ncbi:9606">human</span>
###xml 1078 1083 <span type="species:ncbi:10090">mouse</span>
###xml 1107 1112 <span type="species:ncbi:10090">mouse</span>
###xml 1303 1308 <span type="species:ncbi:10090">mouse</span>
###xml 1516 1521 <span type="species:ncbi:9606">human</span>
###xml 1663 1668 <span type="species:ncbi:10090">mouse</span>
To determine the tissue distribution of these splice variants, 20 mug of C57BL/6 mouse tissue lysates was Western-blotted with each of the anti-(splice-variant) antibodies as well as the anti-pan-PIPKIgamma antibody. As shown in Figure 3(D), each of the PIPKIgamma splice variants displays a distinct expression pattern in mouse tissue. Consistent with previous reports, PIPKIgamma_i2 is most strongly expressed in brain tissue [26,32,36], but is also expressed in greater quantities in the heart and lungs. PIPKIgamma_i4 is strongly expressed in the pancreas and liver, but is also present in lesser quantities in the brain, heart, lung and kidney. PIPKIgamma_i5 is present in large amounts in the heart and large intestine, but is also present in the lung, pancreas and thyroid, and, to a lesser extent, brain, stomach and kidney. Interestingly, the apparent molecular mass of the PIPKIgamma_i5 mouse orthologue is approx. 5-10 kDa lower than that of the human form. This size shift could be the result of a second alternative splicing event that has removed a portion of the mouse PIPKIgamma_i5 mRNA. In mouse brain tissue lysates, two bands appear that are immunoreactive to the anti-PIPKIgamma_i5 polyclonal antibody, but neither corresponds to the major species of PIPKIgamma_i5 observed in other mouse tissues (Figure 3D). It is possible that the lower band is the brain-specific PIPKIgamma splice variant (PIPKIgamma_i3), identified by Giudici et al. [32,33], which shares partial sequence homology with the human PIPKIgamma_i5 variant described here [32,33]. The upper band is approx. 100 kDa, and, in view of its molecular mass, is potentially the full mouse orthologue of PIPKIgamma_i5. Importantly, the expression profiles of each of the PIPKIgamma splice variants are indicative of a specialized role for each of these proteins in a particular tissue.
###end p 47
###begin title 48
###xml 77 78 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PIPKIgamma_i4 and PIPKIgamma_i5 possess lipid kinase activity towards PtdIns4P
###end title 48
###begin p 49
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 133 141 133 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 587 588 567 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 607 615 587 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 656 657 636 637 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 745 746 717 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 768 770 736 738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 789 797 757 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 830 838 798 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 870 871 838 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1016 1017 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1059 1067 1027 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The type-I PIPKs synthesize PtdIns(4,5)P2 using the cellular pool of PtdIns4P as substrate [1,3,23]. This reaction can be reproduced in vitro using recombinant or immunoprecipitated PIPKI enzyme and PtdIns4P-containing micelles or liposomes [34]. The kinase domains of PIPKIgamma_i4 and PIPKIgamma_i5 are identical in sequence composition with that of the previously characterized PIPKIgamma splice variants. However, we wanted to explore whether the additional amino acids present at the C-terminus of PIPKIgamma_i4 and PIPKIgamma_i5 affected the activity of the enzymes towards PtdIns4P. To test this, an in vitro kinase activity assay was done using His6-tagged recombinant PIPKIgamma splice variants or PIPKIalpha (positive control), PtdIns4P micelles, and [gamma-32P]ATP. As shown in Figure 4, no apparent differences in the in vitro kinase activity towards PtdIns4P exist between the four enzymes. This result was confirmed by substituting Folch Brain Extract as substrate in these assays (results not shown) [9]. These results suggested that, at least in vitro, the C-terminal extensions of PIPKIgamma splice variants do not directly have an impact on the kinase activity of the enzymes.
###end p 49
###begin title 50
PIPKIgamma splice variants display PtdIns(4)P 5-kinase activity
###end title 50
###begin p 51
###xml 38 39 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 121 122 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 143 145 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 189 197 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Either 1 mug (1X) or 5 mug (5X) of His6-tagged recombinant PIPKIalpha or PIPKIgamma splice variants were added to PtdIns4P micelles and [gamma-32P]ATP for 5 min at room temperature to test in vitro PIPK activity, and lipids extracted from the reaction mixtures were separated by TLC. Purified BSA was incubated under the same conditions as a control.
###end p 51
###begin title 52
PIPKIgamma_i4 is a nuclear-targeted splice variant
###end title 52
###begin p 53
###xml 353 354 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 355 356 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 357 359 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 360 362 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 363 365 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
The 28-amino-acid C-terminal extension that is present on PIPKIgamma_i2 is directly responsible for the targeting of this splice variant to focal adhesions in mesenchymal cells and to cell-cell contacts in polarized epithelial cells. This occurs via the association of this unique C-terminus with talin or E-cadherin and AP (adaptor protein) complexes [8,9,17,27,28]. Therefore, it is likely that the unique C-terminal PIPKIgamma variants described here also facilitate protein-protein interactions which target each splice variant to a discrete location within the cell.
###end p 53
###begin p 54
###xml 479 487 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 643 644 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 645 647 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 768 776 736 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 956 964 920 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 974 982 938 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1209 1211 1169 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1212 1214 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1314 1323 1270 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figures 5</xref>
###xml 1329 1330 1285 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
###xml 1851 1859 1783 1791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2018 2026 1942 1950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 2270 2278 2186 2194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1002 1005 <span type="species:ncbi:10116">rat</span>
To explore the subcellular targeting of these new splice variants, we stained cells with polyclonal antibodies to pan-PIPKIgamma, PIPKIgamma_i4 and PIPKIgamma_i5. Unfortunately, the PIPKIgamma_i5 polyclonal antibody resulted in very poor staining in all cell lines tested. When MCF10A cells were stained with a anti-pan-PIPKIgamma polyclonal antibody, we observed PIPKIgamma localization largely at cell-cell contacts where it co-localizes with the adhesion molecule E-cadherin (Figure 5A). A portion of this staining is likely to be indicative of PIPKIgamma_i2, the functional contribution of which to E-cadherin biology is well established [4,17]. However, the anti-pan-PIPKIgamma polyclonal antibody also shows some reactivity towards punctuate nuclear structures (Figure 5A). Interestingly, our anti-PIPKIgamma_i4 polyclonal antibody indicated a localization of this variant to subnuclear structures, and, to a lesser extent, the cytoplasm, in MCF10A (Figure 5A), HeLa (Figure 5B), and NRK (normal rat kidney) cells (results not shown). Another type-I PIPK, namely PIPKIalpha, targets to subnuclear sites known as 'nuclear speckles'. where it associates with splicing factors to regulate mRNA processing [22,37]. PIPKIgamma_i4 staining co-localized with SC-35, a marker of nuclear speckles, but not nucleolin (Figures 5A and 5B). This result is striking, as PIPKIgamma has not been previously identified as a nuclear PIPKI. To further assess the targeting of PIPKIgamma_i4, HeLa cells were fractionated into their nuclear and cytosolic components, and these lysates were subjected to Western blotting with anti-PIPKIgamma polyclonal antibodies. Blotting with the anti-pan-PIPKIgamma antibody indicated that PIPKIgamma is mainly located in the cytosolic fraction, but a discernable amount of PIPKIgamma was present in the nuclear fraction as well (Figure 5C). In agreement with the results from blotting with anti-pan-PIPKIgamma antibody, PIPKIgamma_i4 was identified in both the cytoplasmic and nuclear fractions (Figure 5C). Interestingly, PIPKIgamma_i4 appeared as a doublet in the nuclear, but not cytoplasmic, fraction. This probably indicates post-translational modification of PIPKIgamma_i4, which is consistent with our observations of this splice variant in Figure 3(C). Taken together, these results support the presence of PIPKIgamma_i4 in the nucleus and suggest that PIPKIgamma_i4 could be functionally active in cytoplasmic as well as nuclear processes.
###end p 54
###begin title 55
PIPKIgamma_i4 is a nuclear-targeted phosphoinositide kinase
###end title 55
###begin p 56
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 15 16 15 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 428 429 415 416 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
(A) MCF10A or (B) HeLa cells were grown on coverslips, fixed in methanol, and probed with antibodies for pan-PIPKIgamma (green), PIPKIgamma_i4 (Igamma_i4; green), E-cadherin (ECD) (red), and SC-35 (red). Co-localization of red and green immunofluorescence channels is indicated in yellow. DAPI (4',6-diamidino-2-phenylindole) staining was omitted from merged images (Merge) of labelled nuclei. The scale bar represents 10 mum. (C) The cytosolic (Cyto) and nuclear (Nuc) protein fractions of HeLa cells were separated as described in the Experimental section, then subject to Western blotting with anti-PIPKIgamma_i4 and pan-PIPKIgamma antibodies. Lamin beta1 and beta-tubulin were Western-blotted as controls for the nuclear and cytosolic fractions respectively. Abbreviation: WCL, whole-cell lysate.
###end p 56
###begin title 57
PIPKIgamma_i5 targets to discrete cytoplasmic domains
###end title 57
###begin p 58
###xml 338 346 326 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 737 745 717 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1050 1058 1014 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1226 1237 <span type="species:ncbi:9606">participant</span>
As our attempts to utilize the anti-PIPKIgamma_i5 polyclonal antibody for immunofluorescenve staining were unsuccessful, HA-tagged PIPKIgamma_i5 was expressed in HeLa cells and its localization was observed. PIPKgamma_i5 was found to target to the plasma membrane as well as to punctuate and enlarged cytoplasmic vesicle-like structures (Figure 6). To confirm the nature of these structures, HeLa cells transfected with PIPKIgamma_i5 were stained for various markers of endosomal compartments. PIPKIgamma_i5 was found to partially co-localize with a subset of vesicles that stained positive for TfnR (recycling endosomes), EEA1 (early endosomes), CD63 (multi-vesicular bodies/late endosomes), and, to a lesser extent, LAMP1 (lysosomes) (Figure 6). As we observed some co-localization of PIPKIgamma_i5 with LAMP1, this could indicate active degradation of PIPKIgamma_i5. However, degradation of PIPKIgamma_i5 was not observed, as treatment of these cells with chloroquine did not alter PIPKIgamma_i5 expression levels (results not shown). As shown in Figure 6, only a subset of PIPKIgamma_i5-positive vesicles co-localized with any of these endosomal markers. However, these results suggest that PIPKIgamma_i5 may be an active participant in endosomal trafficking events at multiple locations within the endosomal system.
###end p 58
###begin title 59
PIPKIgamma_i5 localizes to endosomal compartments
###end title 59
###begin p 60
HeLa cells expressing HA-tagged PIPKIgamma_i5 were fixed in paraformaldehyde and stained with anti-HA (green) and antibodies towards TfnR (recycling endosomes), EEA1 (early endosomes), CD63 (multi-vesicular bodies/late endosomes) and LAMP-1 (lysosomes) (all in red). Yellow areas indicate co-localization of red and green immunofluorescence signals. The inset figures are 175% zooms of the outlined area. The scale bar represents 10 mum.
###end p 60
###begin title 61
PIPKIgamma_i5 is functionally distinct from PIPKIgamma_i2
###end title 61
###begin p 62
###xml 188 196 176 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 220 223 208 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">647</sup>
###xml 229 232 217 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">653</sup>
###xml 343 346 327 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">647</sup>
###xml 352 355 336 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">653</sup>
###xml 479 480 451 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 500 502 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 503 505 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 506 508 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 509 511 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 512 514 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 727 735 679 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Although the C-terminus of PIPKIgamma_i4 is quite distinct from that of the other human splice variants, the C-terminus of PIPKIgamma_i5 shows partial similarity to that of PIPKIgamma_i2 (Figure 1C). In particular, the W647VYSPLH653 (one-letter amino acid code) motif present in PIPKIgamma_i2 shows a high level of similarity to the sequence W647IYSPRH653 in the C-terminus of PIPKIgamma_i5. In PIPKIgamma_i2, this sequence modulates the association of PIPKIgamma_i2 with talin [1] and AP complexes [13,14,16-18,38]. To determine potential PIPKIgamma_i5 functional overlap with PIPKIgamma_i2, HeLa cells expressing PIPKIgamma_i5 were stained for endogenous talin or alpha-adaptin. PIPKIgamma_i5 did not co-localize with talin (Figure 7A) or alpha-adaptin (results not shown) in HeLa cells. In addition, PIPKIgamma_i5 did not co-immunoprecipitate with talin1, talin2 or alpha-adaptin (results not shown), confirming that, although the C-terminus of PIPKIgamma_i5 contains this similar sequence, it does not target to the same cellular domains and probably cannot functionally compensate for PIPKIgamma_i2.
###end p 62
###begin title 63
Localization of PIPKIgamma_i5 is distinct from that of PIPKIgamma_i2
###end title 63
###begin p 64
###xml 95 96 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 139 140 135 136 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
HeLa cells expressing HA-tagged PIPKIgamma_i5 were fixed in paraformaldehyde and stained with (A) anti-HA (green) and anti-talin (red) or (B) anti-HA (green) and anti-N-cadherin (NCD) (red) antibodies. Yellow areas indicate co-localization of red and green immunofluorescence signals. The inset figures are 175% zooms of the outlined area. The scale bar represents 10 mum.
###end p 64
###begin p 65
###xml 247 248 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 248 249 240 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 337 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 582 584 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 585 587 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 744 751 716 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 932 940 896 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1065 1067 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1143 1151 1099 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1311 1312 1263 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1312 1313 1264 1265 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
PIPKIgamma_i2 directly associates with E-cadherin in polarized epithelial cells, both at cell-cell contacts and in TfnR-positive recycling endosomes, and the targeting of E-cadherin to the plasma membrane by PIPKIgamma_i2 requires both PtdIns(4,5)P2 generation and the association of PIPKIgamma_i2 with AP1B via its unique C-terminus [17]. HeLa cells do not express E-cadherin; instead, cell-cell contacts in HeLa cells are mediated by N-cadherin, another member of the classical cadherin family. N-cadherin also directly associates with PIPKIgamma via its conserved kinase domain [17,39] and, as the kinase domain of PIPKIgamma_i5 is identical with that of PIPKIgamma_i2, we tested to see whether PIPKIgamma_i5 could associate with N-cadherin in vivo. In HeLa cells co-stained for PIPKIgamma_i5 and N-cadherin, we observed co-localization of PIPKIgamma_i5 and N-cadherin at both cell-cell contacts and within cytoplasmic vesicles (Figure 7B). In addition, this targeting of PIPKIgamma_i5 required kinase activity, as a kinase-dead mutant (D316A) of PIPKIgamma_i5 [17] localized diffusely within cells and did not co-localize with N-cadherin (Figure 7B). However, N-cadherin-based cell-cell junctions were not disrupted in HeLa cells expressing PIPKIgamma_i5 D316A, indicating that the generation of PtdIns(4,5)P2 by PIPKIgamma_i5 is not required for the trafficking of N-cadherin to the plasma membrane. Taken together, these results are consistent with a functionally distinct role for PIPKIgamma_i5 in cadherin biology.
###end p 65
###begin title 66
DISCUSSION
###end title 66
###begin p 67
###xml 775 777 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 658 663 <span type="species:ncbi:9606">Human</span>
The popular nomenclature used for splice variants of PIPKIgamma, including those based on amino acid composition or apparent molecular mass, suffers from ambiguity. Splice variants derived from different species may contain similar exons and serve identical biological functions, but often differ in amino acid number and consequently their molecular mass. In addition, PIPKIgamma splice variants are post-translationally modified, which alters their apparent molecular mass on gel electrophoresis. In the present paper we have proposed and implemented a standardization of nomenclature which conforms to the HUGO Genetic Nomenclature Committee () and HGVS (Human Genome Variation Society) () guidelines for transcripts and protein products respectively of the PIP5K1C gene [40]. Continued use of this standardized nomenclature will greatly simplify communication between investigators who study PIPKIgamma biology.
###end p 67
###begin p 68
###xml 398 399 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 400 401 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 402 403 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 404 406 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 686 687 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 687 688 675 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 843 844 827 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 844 845 828 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 857 858 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 859 860 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 861 862 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 863 865 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
Alternative splicing of RNA transcripts is an efficient cellular mechanism that increases the diversity of its protein products, thereby enhancing the overall functional specificity of a particular protein family. Much recent work has been devoted to delineating the mechanisms by which the unique C-terminal domain of PIPKIgamma_i2 is able to confer functional specificity on this splice variant [1,3,4,41]. PIPKIgamma_i2 functions by its C-terminus associating with protein-targeting factors (i.e., talin, AP complexes), which then target the kinase to focal adhesions or cell-cell contacts respectively. Once targeted to its site of function, PIPKIgamma_i2 then generates PtdIns(4,5)P2, which regulates the activities of proteins in the vicinity. Importantly, several proteins that directly associate with PIPKIgamma_i2 are also PtdIns(4,5)P2 effectors [1,3,4,41]. In the present paper we have described two previously undefined splice variants of the PIP5KIC gene, PIPKI_i4 and PIPKIgamma_i5, each of which contains a unique C-terminal domain. It is very probable that these unique C-termini direct the specific functions of PIPKIgamma_i4 and PIPKIgamma_i5 via the association of each kinase with distinct protein-targeting factors in a manner that parallels PIPKIgamma_i2. By this mechanism, the results presented here suggest that PIPKIgamma_i4 and PIPKIgamma_i5 may fill specific functional roles within the nucleus and endosomal transport system respectively.
###end p 68
###begin p 69
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 321 323 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 324 326 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 354 355 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 355 356 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 539 541 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 542 544 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 876 878 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 980 982 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1014 1015 982 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1015 1016 983 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1119 1121 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1214 1215 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1215 1216 1180 1181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The existence of a nuclear phosphoinositide signalling pathway that is independent of the cytoplasmic phosphoinositide cycle has been established, albeit that it remains relatively poorly defined [24]. Several nuclear phosphoinositide kinases have been identified, including another type-I PtdIns4P 5-kinase, PIPKIalpha [20,24]. Recently, the PtdIns(4,5)P2 generated by PIPKIalpha at sites of concentrated pre-mRNA processing factors known as nuclear speckles was shown to regulate the activity of the nuclear poly(A) polymerase Star-PAP [22,37]. Interestingly, our data indicates several striking parallels between PIPKIalpha and our newly discovered PIPKIgamma_i4 splice variant. First, endogenous PIPKIgamma_i4 was found in both the nuclear and cytoplasmic fractions of HeLa cells and also co-localizes with nuclear-speckle markers, both in a manner similar to PIPKIalpha [20]. However, endogenous PIPKIalpha, but not PIPKIgamma, was detectable in Star-PAP immunoprecipitates [22]. Moreover, another PtdIns(4,5)P2-generating enzyme, PIPKIIbeta, targets to nuclear speckles and also does not associate with Star-PAP [22], which supports the hypothesis that there are several discrete pools of nuclear PtdIns(4,5)P2 that are generated by PIPKIgamma_i4, PIPKIalpha or PIPKIIbeta. In other words, the specific targeting of these kinases and their association with a unique subset of proteins allows each to fill a distinct functional niche in nuclear phosphoinositide signalling pathways.
###end p 69
###begin p 70
###xml 186 188 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 189 191 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 615 623 595 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
Secondly, it is important to note that PIPKIgamma_i4 is not visible in the nucleus upon overexpression, a localization phenotype that is identical with that of overexpressed PIPKIalpha [20,22]. However, endogenous PIPKIalpha and PIPKIgamma_i4 have been observed in both the cytoplasm and the nucleus, which leads us to speculate that the nuclear targeting of these kinases must be regulated in some manner. It is possible that post-translational modification of the unique C-terminus of PIPKIgamma_i4, or interaction of a nucleartargeted protein with this sequence, could modulate its nuclear entry. As observed in Figure 5(C), PIPKIgamma_i4 appears as a doublet in the nuclear, but not in the cytosolic, fraction of HeLa cells. Therefore, nuclear PIPKIgamma_i4 could be modified as a signal for nuclear retention or functional specificity within a nuclear subdomain. However, evidence supporting these speculations is lacking, and further investigation is required to determine the method of import as well as the potential nuclear functions of PIPKIgamma_i4.
###end p 70
###begin p 71
###xml 78 80 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 418 420 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 506 511 <span type="species:ncbi:10090">mouse</span>
###xml 562 567 <span type="species:ncbi:9606">human</span>
Interestingly, the PIPKIgamma_i3 splice variant identified by Giudici et al. [33] shares 75% sequence identity with the first 20 amino acids of the PIPKIgamma_i5 C-terminus. In agreement with our data, Guidici et al. reported that PIPKIgamma_i3 localized to vesicle-like and punctuate cytoplasmic structures when expressed in non-neuronal cells, where they also observed modest co-localization with vesicular markers [33]. However, as the splice variant identified by Giudici et al. seems to be limited to mouse neurons, we propose that the much more ubiquitous human PIPKIgamma_i5 could serve to perform similar biological functions in non-neuronal cells.
###end p 71
###begin p 72
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 196 197 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 438 439 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 439 440 435 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 603 611 599 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 613 614 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 876 877 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 877 878 869 870 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 961 968 953 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 993 1018 985 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schizosaccharomyces pombe</italic>
###xml 1020 1021 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 993 1018 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
The role of phosphoinositides in the regulation of the endosomal network has been well defined for 3'-phosphorylated polyphosphoinositides [42-44], but less is known about the role of PtdIns(4,5)P2 in these signalling pathways. However, it is probable that PtdIns(4,5)P2 may also be a potent regulator of endosomal transport [45,46], and the targeting of PIPKIgamma_i5 to endosomal compartments suggests that the generation of PtdIns(4,5)P2 could regulate endosomal system function or even transport between endosomal subdomains. As the type-I PIPKs have been shown to phosphorylate 3-phosphoinositides in vitro [3], an alternative explanation is that, given a certain subcellular condition or protein interaction partner, the substrate preference of PIPKIgamma_i5 could be changed to utilize 3-phosphoinositides, thereby generating lipid messengers in addition to PtdIns(4,5)P2. However, this shift in PIPK substrate preference has not yet been shown to occur in vivo in organisms other than Schizosaccharomyces pombe [3].
###end p 72
###begin p 73
###xml 798 800 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
The significance of the sequence similarity between the talin and AP complex binding/regulatory site that is present in the C-terminus of PIPKIgamma_i2, and its 'sister' sequence that is present in the C-terminus of PIPKIgamma_i5 cannot be overlooked. Our data indicate that, in the light of this similarity, PIPKIgamma_i5 does not associate with talin or APs and is not targeted in a manner similar to PIPKIgamma_i2. Although both PIPKIgamma_i2 and PIPKIgamma_i5 colocalize with cadherins, the mechanism by which PIPKIgamma_i5 is involved in N-cadherin function likely differs from that of PIPKIgamma_i2. When kinase inactive PIPKIgamma_i2 or PIPKIgamma_i1 (which lacks a C-terminal tail) was expressed in polarized epithelial cells, trafficking of E-cadherin to the plasma membrane was hindered [17], indicating that both kinase activity as well as the unique C-terminus of PIPKIgamma_i2 is required for efficient basolateral targeting of E-cadherin. HeLa cells expressing PIPKIgamma_i5 D316A showed no apparent inhibition of N-cadherin trafficking to cell-cell contacts, but co-localization of PIPKIgamma_i5 and N-cadherin was lost. These data suggest that PIPKIgamma_i5 potentially regulates the post-endocytic trafficking of N-cadherin rather than its exocytosis. Since PIPKIgamma_i5 is partially localized at several types of endosomal compartments, this splice variant is positioned to regulate the endosomal trafficking of N-cadherin, E-cadherin or other proteins at multiple steps within the endosomal system. However, further study is required to resolve the nature of the endosomal compartment at which PIPKIgamma_i5 and N-cadherin co-localize, and to determine the extent of regulation by PIPKIgamma_i5.
###end p 73
###begin title 74
AUTHOR CONTRIBUTION
###end title 74
###begin p 75
Nicholas J. Schill performed the experiments, analysed and interpreted the data and wrote the manuscript. Richard A. Anderson provided scientific guidance and edited the manuscript prior to submission.
###end p 75
###begin title 76
ACKNOWLEDGEMENT
###end title 76
###begin p 77
We thank Dr Christy Barlow (Department of Pharmacology, University of Wisconsin Medical School, Madison, WI, U.S.A.) for discussion and comments on the manuscript prior to submission.
###end p 77
###begin title 78
FUNDING
###end title 78
###begin p 79
###xml 31 60 31 60 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="gs1">National Institutes of Health</funding-source>
###xml 75 90 75 90 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs1">T32 HL007899-07</award-id>
###xml 108 157 108 157 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="gs2">American Heart Association predoctoral fellowship</funding-source>
###xml 172 180 172 180 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs2">0615532Z</award-id>
###xml 205 234 205 234 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="gs3">National Institutes of Health</funding-source>
###xml 251 266 251 266 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs3">RO1 GM057549-14</award-id>
###xml 271 282 271 282 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="gs3">CA104708-05</award-id>
This work was supported by the National Institutes of Health [grant number T32 HL007899-07 (to N.J.S.)]; an American Heart Association predoctoral fellowship [grant number 0615532Z (to N. J. S.)]; and the National Institutes of Health [grants numbers RO1 GM057549-14 and CA104708-05 (to R. A. A.)].
###end p 79
###begin article-title 80
###xml 37 38 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Movin' on up: the role of PtdIns(4,5)P2 in cell migration
###end article-title 80
###begin article-title 81
Inositol-lipid binding motifs: signal integrators through protein-lipid and protein-protein interactions
###end article-title 81
###begin article-title 82
A conspicuous connection: structure defines function for the phosphatidylinositol-phosphate kinase family
###end article-title 82
###begin article-title 83
###xml 35 36 35 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Out, in and back again: PtdIns(4,5)P2 regulates cadherin trafficking in epithelial morphogenesis
###end article-title 83
###begin article-title 84
Phosphoinositide regulation of the actin cytoskeleton
###end article-title 84
###begin article-title 85
Membrane ruffling requires coordination between type Ialpha phosphatidylinositol phosphate kinase and Rac signalling
###end article-title 85
###begin article-title 86
Talin: an emerging focal point of adhesion dynamics
###end article-title 86
###begin article-title 87
Type Igamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions
###end article-title 87
###begin article-title 88
Recruitment and regulation of phosphatidylinositol phosphate kinase type Igamma by the FERM domain of talin
###end article-title 88
###begin article-title 89
Phosphatidylinositol phosphate 5-kinase Ibeta recruits AP-2 to the plasma membrane and regulates rates of constitutive endocytosis
###end article-title 89
###begin article-title 90
###xml 20 21 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Impaired PtdIns(4,5)P2 synthesis in nerve terminals produces defects in synaptic vesicle trafficking
###end article-title 90
###begin article-title 91
Phosphatidylinositol phosphate kinase type Igamma regulates dynamics of large dense-core vesicle fusion
###end article-title 91
###begin article-title 92
Stimulation of phosphatidylinositol kinase type I-mediated phosphatidylinositol 4,5-bisphosphate synthesis by AP-2mu-cargo complexes
###end article-title 92
###begin article-title 93
Role of activation of PIP5Kgamma661 by AP-2 complex in synaptic vesicle endocytosis
###end article-title 93
###begin article-title 94
ARF6 stimulates clathrin/AP-2 recruitment to synaptic membranes by activating phosphatidylinositol phosphate kinase type Igamma
###end article-title 94
###begin article-title 95
Type Igamma661 phosphatidylinositol phosphate kinase directly interacts with AP2 and regulates endocytosis
###end article-title 95
###begin article-title 96
Type Igamma phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with mu1B adaptin
###end article-title 96
###begin article-title 97
Clathrin regulates the association of PIPKIgamma 661 with the AP-2 adaptor beta 2 appendage
###end article-title 97
###begin article-title 98
PIP5Kigamma is required for cardiovascular and neuronal development
###end article-title 98
###begin article-title 99
Phosphoinositide signalling pathways in nuclei are associated with nuclear speckles containing pre-mRNA processing factors
###end article-title 99
###begin article-title 100
Stress-ING out: phosphoinositides mediate the cellular stress response
###end article-title 100
###begin article-title 101
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
A PtdIns(4,5)P2-regulated nuclear poly(A) polymerase controls expression of select mRNAs
###end article-title 101
###begin article-title 102
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Phosphatidylinositol phosphate kinases put PI4,5P2 in its place
###end article-title 102
###begin article-title 103
Nuclear phosphoinositide kinases and inositol phospholipids
###end article-title 103
###begin article-title 104
Phosphatidylinositol-4-phosphate 5-kinase gamma is associated with cell-cell junction in A431 epithelial cells
###end article-title 104
###begin article-title 105
Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family
###end article-title 105
###begin article-title 106
Type Igamma phosphatidylinositol phosphate kinase is required for EGF-stimulated directional cell migration
###end article-title 106
###begin article-title 107
Tyrosine phosphorylation of type Igamma phosphatidylinositol phosphate kinase by Src regulates an integrin-talin switch
###end article-title 107
###begin article-title 108
Regulation of the interaction between PIPKIgamma and talin by proline-directed protein kinases
###end article-title 108
###begin article-title 109
Phosphatidylinositol phosphate kinase type Igamma directly associates with and regulates Shp-1 tyrosine phosphatase
###end article-title 109
###begin article-title 110
###xml 51 53 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Critical role of PIP5KIgamma87 in InsP3-mediated Ca2+ signalling
###end article-title 110
###begin article-title 111
A novel neuronal-specific splice variant of Type I phosphatidylinositol 4-phosphate 5-kinase isoform gamma
###end article-title 111
###begin article-title 112
###xml 81 82 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The intracellular localisation and mobility of Type Igamma phosphatidylinositol 4P 5-kinase splice variants
###end article-title 112
###begin article-title 113
The activation loop of phosphatidylinositol phosphate kinases determines signalling specificity
###end article-title 113
###begin article-title 114
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Lineage-specific biology revealed by a finished genome assembly of the mouse
###end article-title 114
###begin article-title 115
###xml 38 39 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 39 40 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
PIP kinase Igamma is the major PI(4,5)P2 synthesizing enzyme at the synapse
###end article-title 115
###begin article-title 116
Star-PAP is associated with and phosphorylated by the protein kinase CKIalpha which is also required for expression of select star-PAP target messenger RNA
###end article-title 116
###begin article-title 117
Signals for sorting of transmembrane proteins to endosomes and lysosomes
###end article-title 117
###begin article-title 118
Phosphatidylinositol 4,5-bisphosphate produced by PIP5KIgamma regulates gelsolin, actin assembly, and adhesion strength of N-cadherin junctions
###end article-title 118
###begin article-title 119
###xml 15 20 <span type="species:ncbi:9606">human</span>
Guidelines for human gene nomenclature
###end article-title 119
###begin article-title 120
###xml 91 92 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 92 93 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The phosphoinositide kinase PIP5K that produces the versatile signalling phospholipid PI4,5P2
###end article-title 120
###begin article-title 121
Phosphatidylinositol 3,5-bisphosphate and Fab1p/PIKfyve underPPIn endo-lysosome function
###end article-title 121
###begin article-title 122
Phosphoinositides in constitutive membrane traffic
###end article-title 122
###begin article-title 123
###xml 32 37 <span type="species:ncbi:9606">human</span>
Endosomal phosphoinositides and human diseases
###end article-title 123
###begin article-title 124
Cooperation of phosphoinositides and BAR domain proteins in endosomal tubulation
###end article-title 124
###begin article-title 125
###xml 18 24 <span type="species:ncbi:10090">murine</span>
Overexpression of murine phosphatidylinositol 4-phosphate 5-kinase type Ibeta disrupts a phosphatidylinositol 4,5 bisphosphate regulated endosomal pathway
###end article-title 125

